天美传媒

Dr. Pavia is a pediatric infectious disease expert who can provide expert commentary on vaccines, infectious disease and related trending topics. He has become a trusted source for top national media.

He received his bachelor's degree and medical degree at Brown University. He trained in internal medicine and pediatrics at Dartmouth and the University of Utah. At the Centers for Disease Control and Prevention, Dr. Pavia trained in Public Health Epidemiology as an Epidemic Intelligence Service (EIS) officer and a Preventive Medicine Resident. Additionally, Dr. Pavia completed a fellowship in pediatric and adult infectious diseases at the University of Utah. He joined the faculty at the University of Utah in 1991. In 2003 Dr. Pavia became the George and Esther Gross Presidential Professor and Chief of the Division of Pediatric Infectious Diseases, where he mentors a dynamic and productive team of faculty and fellows. He also serves as Director of Hospital Epidemiology at Primary Children's Hospital and Associate Director of Antimicrobial Stewardship. Dr. Pavia is a member of the Society for Pediatric Research. He is a Fellow of the American Academy of Pediatrics, the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Dr. Pavia is a member of the National Academy of Science Engineering and Medicine Forum on Preparedness. He was recently Vice Chair and Chair of the Program Committee for IDWeek and served two terms on the CDC Board of Scientific Counselors. He has served as a member of the Board of Directors the Infectious Disease Society of America (IDSA) and past chair of the Pandemic Influenza Task Force and past Chair of the National and Global Public Policy Committee. Dr. Pavia served as a member of the National Vaccine Advisory Committee and chaired the Vaccine Safety Working Group, was an inaugural member of the National Biodefense Science Board (NBSB) and chaired the Influenza Working Group, and co-chaired the Personal Preparedness Working Group of the NBSB from 2008-2010. Dr. Pavia has served on several Institute of Medicine Committees including 鈥淎ntivirals for Pandemic Influenza: Guidance on Developing and Distribution and Dispensing System,鈥� and 鈥淧repositioned Medical Countermeasure for the Public,鈥� and is a frequent consultant for CDC. He is an associate Editor of the Sanford Guide to Antimicrobial Therapy and is on the editorial board the Journal of the Pediatric Infectious Disease Society and a reviewer for numerous journals. He has published more than 250 peer-reviewed scientific articles, textbook chapters, reviews and scientific abstracts. His research interests include the epidemiology of influenza and other emerging respiratory infections, pneumonia, vaccine preventable diseases, emerging infections, and HIV/ AIDS, with a particular interest in infections of pregnant women and their children. He has been the principal investigator or co-investigator on grants from the National Institutes of Health, the Bill and Melinda Gates Foundation, and the Centers for Disease Control and Prevention.

Dr. Pavia received his undergraduate and medical degrees from Brown University. He completed his residency at Dartmouth Hitchcock Medical Center and served as Chief Resident. He then served as an officer in the Epidemic Intelligence Service at the Centers for Disease Control and Prevention and completed a residency in Preventive Medicine. He completed fellowship training in pediatric and adult infectious diseases at the University of Utah. Dr. Pavia is currently the George and Esther Gross Presidential Professor at the University of Utah and is Chief of the Division of Pediatric Infectious Diseases. His academic interests include the epidemiology, diagnosis and management of emerging infectious diseases including influenza, respiratory infections and diarrheal diseases. He is also keenly interested in HIV/AIDS and has been involved in HIV clinical care and research since the 1980s.

Sean is an assistant professor in pulmonary and critical care medicine who originally hails from the Commonwealth of Virginia. His clinical and research interests include care for patients with complex lung disease, with a focus on idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases. He sees patients at the Farmington and University Hospital pulmonary clinics. He has expertise in the pulmonary care and pathology of patients with the deadly illness caused by vaping, e-cigarette or vaping use associated with lung injury (EVALI), and with COVID-19.

Robert Paine III, M.D. is an experienced Pulmonary and Critical Care Medicine physician who has been board-certified in Internal Medicine, Pulmonary Medicine and Critical Care Medicine. He cares for outpatients with a wide variety of pulmonary problems and has a particular interest in chronic obstructive pulmonary disease (COPD) and unexplained shortness of breath. He has a major interest in the care of critically ill patients in the medical intensive care unit (MICU) and has an ongoing research program related to the causes and treatment of acute lung injury.

Dr. Paul J. Chittick is an infectious disease specialist in Royal Oak, Michigan and is affiliated with multiple hospitals in the area, including Beaumont Hospital-Grosse Pointe and Beaumont Hospital-Royal Oak. He received his medical degree from Wayne State University School of Medicine and has been in practice for 11-20 years. 

Rachel Hess, MD, MS is a Professor of Population Health Sciences and Internal Medicine and the founding Chief of the Division of Health System Innovation and Research (HSIR) program at the University of Utah Schools of the Health Sciences. As a clinician and Health Services Researcher, Dr. Hess brings a unique perspective of translating research into clinical and policy practice. She is the co-principal investigator of one of the original 11 PCORnet Clinical Data Research Networks, PaTH and serves as the co-Director of the Utah CCTS.

Dr. Hess鈥檚 research aims to improve patient-centered outcomes in clinical care. In service of this mission, she seeks to understand the determinants of quality of life, including sexual function, and how the health-related quality of life affects health and cost outcomes. She has conducted cohort studies in midlife women to examine the impact of menopause on health-related quality of life, including sexual functioning. She is currently following a cohort of adults over 50 to characterize the roles of intrapersonal resources, interpersonal relationships, and individual lifestyle in shaping the quality of life across transitions; and the health and healthcare-cost outcomes of quality of life.

Dr. Hess鈥檚 implementation work uses health information technology to engage patients in their care. She has examined the impact of providing patients with guideline-based feedback regarding their health behaviors and health-related quality of life on patient activation and behavior change. Dr. Hess has overseen the development and successful implementation of multiple technology-based programs in primary care. As the director of HSIR, she brings together individuals from across the University of Utah to develop, test, and implement novel approaches that improve health outcomes for the population.

Dr. Hess completed her undergraduate work in mathematics at Washington University, received her medical degree from the University of New Mexico, completed her residency training at Temple University, and completed her general internal medicine and women鈥檚 health fellowships at the University of Pittsburgh.

Dr. Inderpal Randhawa is a leading specialist with board certifications in allergy, immunology, pulmonology, general pediatrics, and internal medicine. He gained interest in food allergy while serving as a sub-investigator in an early study utilizing Omalizumab (Trade name: Xolair). Meanwhile, he was witnessing a dramatic and unprecedented increase in the number of pediatric patients admitted to the intensive care unit as the result of anaphylaxis. The severity and frequency of these cases drove Dr. Randhawa to question the direction of food allergy treatment and motivated him to find more effective solutions than those from clinical trials.

In addition, Dr. Randhawa had experience desensitizing lung transplant patients with life-threatening allergies to critical and indispensable anti-rejection drugs that utilized a patient-specific desensitization protocol. These experiences, and his collaboration with national allergy and immunology specialists, informed Dr. Randhawa鈥檚 precision medicine approach to treating food allergy. Since 2005, he has successfully treated more than 2,000 patients with life-threatening allergies to peanut, tree nuts, milk, egg, wheat, soy, seafood, seeds, and other foods using his unique, research-based Tolerance Induction Program, achieving an unmatched 99% rate of success.

Dr. Randhawa serves as the program director and research coordinator in two fellowship programs at the David Geffen UCLA School of Medicine and UC Irvine 鈥� Miller Children鈥檚 Hospital. In addition, he practices clinical medicine in pulmonary diseases, immune deficiencies, allergy and transplant medicine. Dr. Randhawa is also the Founder and Medical Director of the Translational Pulmonary and Immunology Research Center (TPIRC).

Dr. Randhawa received his medical degree from Northwestern University鈥檚 Feinberg School of Medicine. After completing a combined internal medicine/pediatrics residency, he completed training in Clinical Immunology & Allergy at UCLA and pediatric and adult pulmonology at UC Irvine 鈥� Miller Children鈥檚 Hospital. Dr. Randhawa has authored over 150 peer reviewed abstracts and research publications and has served as primary investigator in over 25 clinical trials.

Dr. Jane Salmon is the Collette Kean Research Professor at Hospital for Special Surgery. She is Professor of Medicine and Professor of Medicine in Obstetrics and Gynecology and Associate Dean, Faculty Affairs at Weill Cornell College of Medicine.

Dr. Salmon鈥檚 research has focused on elucidating mechanisms of tissue injury in lupus and other autoimmune diseases. Her basic, translational and clinical studies have led to a paradigm shift in the understanding of mechanisms of pregnancy loss, cardiovascular disease and end-organ damage in patients with lupus. She identified the critical role of inflammation as a mediator of placental insufficiency and defined new treatment targets.

Dr. Salmon graduated magna cum laude from New York University and earned a medical degree in 1978 from the College of Physicians and Surgeons of Columbia University, where she was the first woman enrolled in their Medical Scientist Training Program. She completed training in internal medicine at The New York Hospital and in rheumatology at Hospital for Special Surgery, where she currently conducts clinical and basic research studies and practices rheumatology. Dr. Salmon has served on the Board of Directors of the American College of Rheumatology and Rheumatology Research Foundation. Dr. Salmon was co-editor of Arthritis and Rheumatism and is currently an Associate Editor of Annals of Rheumatic Diseases. At Hospital for Special Surgery, she is a Director of the Lupus and APS Center of Excellence, Co-Director of the Mary Kirkland Center for Lupus Research.

Professor at the University of Arkansas for Medical Sciences (UAMS), recently received the 2018 Outstanding Adult Immunization Champion award for exceptional dedication to protecting adults from vaccine-preventable diseases.

Hopkins joined UAMS faculty in 1993 and has been a professor in the College of Medicine departments of Pediatrics and Internal Medicine since 2010. In 2012, he was named director of the Division of General Internal Medicine in the Department of Internal Medicine. He is a member of several professional and medical associations and has served on the Executive Committee of the National Influenza Vaccine Summit.

Dr. Linas is a national leader in hepatitis-C virus (HCV) infection and HCV/HIV co-infection comparative- and cost-effectiveness research using computational biology, clinical epidemiology and clinical economics methods. Dr. Linas has an excellent track record of productivity, ample funding from the NIH and CDC, and a growing core of successful trainees. Dr. Linas directs the HIV/HCV core of the Center for Health Economics of Treatment Interventions for Substance Use Disorders, HCV, and HIV, funded by the National Institute on Drug Abuse (NIDA) in collaboration with Cornell, U Penn and Miami.

Sarita A. Mohanty, MD, MPH, MBA, serves as the President and Chief Executive Officer of The SCAN Foundation. The SCAN Foundation is one of the largest foundations in the United States focused on improving the quality of health and life for older adults. Its mission is to advance a coordinated and easily navigated system of high-quality services for older adults that preserve dignity and independence. 

The SCAN Foundation has been a national leader in the development and scaling of person-centered care models for vulnerable adults with complex needs, including those served by Medicare and Medicaid. The foundation has been at the forefront of policy discussions regarding health care for older adults and coordinating services both for older adults and their caregivers.

Previously, Sarita served as the Vice President of Care Coordination for Medicaid and Vulnerable Populations at Kaiser Permanente. Sarita was previously Assistant Professor of Medicine at USC; Chief Medical Officer of COPE Health Solutions, a health care management consulting company; and Senior Medical Director at L.A. Care, the largest U.S. public health plan. Sarita was recently named a National Quality Forum (NQF) Quality Policy Fellow and has served on several NQF committees related to quality measurement. 

Sarita completed her Internal Medicine residency at Beth Israel Deaconess Medical Center and research fellowship at Harvard Medical School. She earned her MD from Boston University, MPH from Harvard University, and MBA from UCLA. She completed undergraduate work at UC Berkeley. She currently is an Associate Professor at the Kaiser Permanente Bernard J. Tyson School of Medicine and is a practicing internal medicine physician with Kaiser Permanente. Sarita enjoys international travel, tennis, and spending time with her husband and three children.

Dr. Carrasquillo is national expert in minority health, health disparities, community based participatory research, access to care and community health worker interventions. He has over twenty years of experience leading large NIH Center grants and randomized trials, totaling over $40 million in funding. His work includes research in cancer, diabetes, cardio-vascular disease, HIV, and most recently in precision medicine.

Dr. Carrasquillo is a Professor of Medicine and Public Health Sciences at the University of Miami鈥檚 Miller School of Medicine.  He is a Puerto Rican born physician who was raised in the Bronx.  He graduated summa cum laude from the Sophie Davis School of Bio-Medical Education at City College and obtained his MD degree from the New York University School of Medicine.  He completed a three-year internal medicine residency at Columbia-Presbyterian Medical Center, Harvard鈥檚 two-year General Medicine Fellowship and an MPH from the Harvard School of Public Health.  Prior to UM, Dr. Carrasquillo was Director of the Center of Excellence in Health Disparities Research at Columbia University.

For the last nine years, he has been the Chief of the Division of General Internal Medicine.  He oversees a clinical, teaching and research enterprise of 44 full-time faculty including six primary care practices and an additional ambulatory hospital-based clinic at Jackson Health System (Miami Public Hospital system).  Dr. Carrasquillo is a national expert in minority health, health disparities, community-based participatory research, access to care and community health worker interventions.  He has over twenty years of experience leading large NIH Center grants and randomized trials, totaling over $60 million in funding.  His work includes research in diabetes, cardiovascular disease, HIV, cancer and most recently in precision medicine.  His research has been published in many of the nation鈥檚 top medical journals and he serves on numerous NIH grant review committees.  He is also active in various national organizations, including numerous current and past leadership roles in the Society of General Internal Medicine, Physicians for a National Health Program, National Hispanic Medical Association and Latinos for National Health Insurance.  In Miami, he is a Board Member of the Miami-Dade Area Health Education Center and the South Florida Health Council.  He is often called upon by the media to discuss his research as well as healthcare topics of particular relevance to the Hispanic community including being a frequent guest on most of the major Latinotelevision networks.

Shaista Malik did her undergraduate work at Stanford University and then did her masters in public health and PhD at UCLA. She has been at UC Irvine since medical school and stayed at UCI for her residency in internal medicine, cardiology fellowship, and was chief cardiology fellow. Dr. Malik is a clinical scientist, she sees patients, teaches, and does research. She is an investigator on several National Institute of Health (NIH) grants, including a career development award, a K23, from NIH (NHLBI) looking at the role of cardiac CT in those with diabetes. She was also recently awarded a prestigious large research project grant, a RO1, looking at the root causes, including the genetics of heart disease. Her research interests include prevention of heart disease and women鈥檚 heart disease. She has helped write national guidelines on training cardiologists as well as American College of Cardiology position paper on cardiovascular imaging in diabetes. She has also edited two books and written several book chapters. She is a section editor for three medical journals. Dr. Malik is the Susan Samueli endowed chair of Integrative Medicine, director of the Susan Samueli Institute for Integrative Medicine, director of the women鈥檚 heart disease program, and the medical director of the preventive cardiology and cardiac rehab program.

Dr. R. Wesley Farr, Lecturer, teaches environmental health, aerospace toxicology, global health, and infectious diseases for the UWF Department of Public Health

Farr is a physician with specialties in Infectious Diseases, Tropical Medicine, Internal Medicine, and Aerospace Medicine.  He continues part-time work in Infectious Diseases.

He was previously on the Infectious Diseases faculty at West Virginia University where he was Director of the International Health program, Director of the Clinical Tropical Medicine and Parasitology Course, and Activity Director of the annual AIDS in West Virginia Conference.

He retired from the US Navy in 2015 after serving as Senior Medical Officer on the USS Harry S Truman, Director of the Military Tropical Medicine Course, and Executive Officer of the Navy and Marine Corps Public Health Center.  He was a medical advisor to the ANA Regional Hospital in Mazar-e-Sharif, Afghanistan.

Before coming to UWF in 2018, he worked at Joint Ambulatory Care Center (VA) and the AIDS Healthcare Foundation.

He received his bachelor鈥檚 degree in Biology, Doctor of Medicine degree, and Masters in Public Health degree from West Virginia University.

Maryam Lustberg, MD, MPH, is Director of the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center, and Chief of Breast Medical Oncology at Yale Cancer Center. She is also an Associate Professor of Medicine (Medical Oncology). She has been recognized for her patient-focused care with awards that include being rated by Forbes as one of the top breast medical oncologists in the nation and named to the Castle Connolly list of 鈥淩egional Top Doctors,鈥� and 鈥淓xceptional Women in Medicine鈥� for 2020. She is currently participating in the American Society of Clinical Oncology (ASCO) Leadership Development Program.

With an emphasis on improving the long-term outcomes for patients with breast cancer who have developed side effects associated with treatment, Dr. Lustberg will continue her research efforts at Yale. She is also focused on investigating novel blood-based biomarkers to identify recurrence and treatment toxicity earlier. She is an NCI-funded investigator and active in both ALLIANCE and SWOG Cancer Cooperative Groups. Dr. Lustberg collaborates widely with researchers from around the world, thriving in creating innovative multidisciplinary scientific teams. Her mentorship has been recognized by numerous awards including Best Teacher Award by Hematology Oncology Fellows and the Shining Star Award for Medical Student Mentorship.
Nationally, Dr. Lustberg is a member of the ASCO Annual Meeting Education Committee, Patient and Survivor Care Education Committee, and Neuropathy Expert Guideline Panel. She is actively engaged in national patient advocacy organizations with a focus on improving shared decision making and increasing patient engagement in clinical trials. In addition, she serves as the President Elect and on the Board of Directors for the international organization Multinational Association of Supportive Care in Cancer (MASCC). She serves as an Associate Editor for the Journal of Cancer Survivorship. In the last decade, she has published over 140 peer-reviewed publications and book chapters.
Dr. Lustberg received her medical degree from the University of Maryland where she also completed her residency and went on to complete a fellowship in medical oncology and in breast medical oncology at The Ohio State University before joining the faculty in 2010. She earned a Master's in Public Health from The Ohio State University in 2013.
Education & Training
MPH
The Ohio State University, Clinical Investigation (2010)
MD
University of Maryland (2003)
Departments & Organizations
Cancer Prevention and ControlCenter for Breast CancerCOPPER CenterInternal MedicineMedical OncologySubset Medical Oncology FacultyYale Cancer CenterYale Medicine

Dr. Steiling is a Pulmonary/Critical Care Physician-Scientist with a longstanding interest in improving the ability to effectively detect, treat, and cure smoking-induced lung diseases such as lung cancer and chronic obstructive pulmonary disease (COPD). She completed her fellowship training in Pulmonary and Critical Care Medicine at Boston University Medical Center, and concurrently completed a Master of Science in Bioinformatics through the Boston University College of Engineering.

Dr. Steiling鈥檚 research centers on improving the diagnosis, treatment and prevention of lung cancer and COPD. Using the airway field of injury hypothesis, which posits that cigarette smoking induces molecular changes throughout the respiratory tract, she has studied alterations in the airway transcriptome that reflect the presence, susceptibility, and progression of smoking-induced lung diseases. She has used whole-genome expression profiling of the bronchial airway epithelium to describe the relationship between upper and lower airway gene expression, and leveraged this information to develop clinically-relevant biomarkers of lung cancer, COPD, and other diseases that affect the lung.

In addition to her translational research, Dr. Steiling has led the implementation of two important clinical programs focused on improving the early detection of lung cancer in at-risk individuals. She founded the Boston Medical Center Lung Nodule Clinic, a sub-specialty referral resource that supports the evidence-based evaluation of incidental pulmonary nodules detected by diagnostic and screening CT scans. She also led the implementation of a multi-disciplinary Lung Cancer Screening Program at Boston Medical Center. Her team was recognized with a 2016 Clinical Quality Improvement Award from the Boston University Medical Center Evans Foundation. She currently co-chairs the Boston Medical Center Lung Cancer Screening Steering Committee. Dr. Steiling sees patients in the Lung Nodule Clinic, multi-disciplinary Thoracic Oncology Clinic and attends in the Medical Intensive Care Unit at Boston Medical Center.

Katherine Baumgarten, MD, is board certified in internal medicine and infectious diseases, and has served as Ochsner Health medical director of infection prevention since 2008. Her expertise includes health care safety and clinical infectious diseases, along with emerging infections and adult vaccines. She has been interviewed by Newsweek magazine, CNN and numerous local outlets on COVID-19, measles and bird flu, among other topics. 
Dr. Baumgarten is a fellow of both the American College of Physicians and the Infectious Diseases Society of America. She is a member of the Society for Healthcare Epidemiology of America and the American Board of Internal Medicine.
A New Orleans native, she attended Washington and Lee University in Lexington, Virginia, and earned a medical degree from Louisiana State University Health Sciences Center - New Orleans. She completed an internship and residency at the University of California at San Francisco and completed an infectious diseases fellowship at Ochsner Medical Foundation in New Orleans.

Dr. Partridge received her MD from Cornell University Medical College in 1995. She completed her residency in internal medicine at the Hospital of the University of Pennsylvania and went on to complete fellowships in medical oncology and hematology at DFCI, MGH and BWH. She also received an MPH from Harvard School of Public Health. She is a medical oncologist who cares for adults with breast cancer, with a particular focus on the unique needs of young patients with breast cancer.  She also leads efforts to optimize cancer survivorship care and research at DFCI.

Barbara Burtness, MD, is a Yale Medicine medical oncologist who sees patients at Yale Cancer Center. She has made it her life’s mission to help people diagnosed with head and neck cancer, which can be a devastating disease even after it is cured—it can impact a person’s appearance, as well as the ability to speak, swallow, and eat.
“Patients often encounter unpleasant outcomes that can include difficulty swallowing solid foods, impaired nutrition, aspiration, and feeding tube dependence,” says Dr. Burtness. “Younger patients may have to deal with these side effects for decades after cancer treatment.”
A careful treatment approach can help prevent these problems. She and her team evaluate the tumor location and decide which primary treatment (surgery or radiation therapy) will best cure the cancer and cause the fewest possible negative outcomes.
A professor of medicine at Yale School of Medicine, Dr. Burtness’ research lab is actively studying new cures for head and neck cancers. “We want to help improve these patients’ quality of life,” she says.

Dr. Kunz is an international leader in the treatment and clinical research of patients with GI malignancies and neuroendocrine tumors (NETs). She holds several leadership positions in the field including President Emeritus of the North American Neuroendocrine Tumor Society, recent past Chair of the Neuroendocrine Tumor Taskforce of the National Cancer Institute, and member of the FDA’s Oncology Drug Advisory Committee. She also currently serves as the Editor-in-Chief for JCO Oncology Advances. In addition to her focus on NETs, she is a leading voice for promoting diversity, equity and inclusion in medicine. She served as the Vice Chief of DEI for the Section of Medical Oncology at Yale School of Medicine and, in 2021, she was awarded ‘Woman Oncologist of the Year’ by Women Leaders in Oncology for her work in promoting gender equity.

Michael Cecchini, MD, is a medical oncologist who specializes in gastrointestinal cancers, including (but not limited to) colorectal, bile duct, pancreas, esophageal, and stomach cancers. He often cares for patients with advanced gastrointestinal cancers and is an investigator in multiple research trials to help them get treatments that are not always available elsewhere.
“Taking care of patients and spending the time to get to know them is the best part of my job,” Dr. Cecchini says. It helps to draw upon the diverse expertise of colleagues at Smilow and those in non-cancer specialties, he adds. “At Yale we have an excellent multidisciplinary team that will work hard to treat your cancer, manage your symptoms, and deliver the care you deserve as a patient.”
Dr. Cecchini was inspired to become a cancer specialist partly because he wanted to have opportunities to perform research to improve options for his patients. “Few specialties are so integrated with close patient relationships and translational research that can dramatically improve the lives of our patients and minimize side effects,” he says. His translational research includes clinical and lab projects to study DNA damage and the immune response, primarily for colorectal cancer. He is the recipient of a Young Investigator Award from the Conquer Cancer Foundation for research focused on metastatic gastric cancer and 2020 Scholar on the Yale Cancer Center K12 Calabresi Immuno-Oncology Training Program.